Unknown

Dataset Information

0

Development of a Method for Screening and Genotyping of HCV 1a, 1b, 2, 3, 4, and 6 Genotypes.

ABSTRACT: The World Health Organization and the World Health Assembly recommended eradicating hepatitis as a public threat by 2030. The accurate genotyping of hepatitis C virus (HCV) is crucial to achieving this goal because it is vital for the selection of anti-HCV therapy required for complete cure of HCV infection. We report the development of a method for accurate genotyping of HCV 1a, 1b, 2, 3, 4, and 6 genotypes. The merits of the developed method for HCV genotyping include (i) requirement of a single polymerase chain reaction (PCR) primer set, (ii) room-temperature detection in 30 min after the PCR, (iii) no need of highly trained professionals, (iv) highly accurate HCV genotyping results afforded by highly specific DNA-DNA hybridization, and (v) probe sequences that can be used on other platforms.

SUBMITTER: Warkad SD 

PROVIDER: S-EPMC7240817 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Development of a Method for Screening and Genotyping of HCV 1a, 1b, 2, 3, 4, and 6 Genotypes.

Warkad Shrikant Dashrath SD   Nimse Satish Balasaheb SB   Song Keum-Soo KS   Kim Taisun T  

ACS omega 20200508 19

The World Health Organization and the World Health Assembly recommended eradicating hepatitis as a public threat by 2030. The accurate genotyping of hepatitis C virus (HCV) is crucial to achieving this goal because it is vital for the selection of anti-HCV therapy required for complete cure of HCV infection. We report the development of a method for accurate genotyping of HCV 1a, 1b, 2, 3, 4, and 6 genotypes. The merits of the developed method for HCV genotyping include (i) requirement of a sing  ...[more]

Similar Datasets

Unknown Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors.
| S-EPMC4027595 | biostudies-literature
Unknown HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b.
| S-EPMC3526494 | biostudies-literature
Unknown Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.
| S-EPMC4415877 | biostudies-literature
Unknown Nested restriction site-specific PCR to detect and type hepatitis C virus (HCV): a rapid method to distinguish HCV subtype 1b from other genotypes.
| S-EPMC88024 | biostudies-literature
Unknown Evolutionary modeling reveals enhanced mutational flexibility of HCV subtype 1b compared with 1a.
| S-EPMC8704487 | biostudies-literature
Unknown Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development.
| S-EPMC5072459 | biostudies-literature
Unknown NS4A protein as a marker of HCV history suggests that different HCV genotypes originally evolved from genotype 1b.
| S-EPMC3145594 | biostudies-literature
Unknown Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6.
| S-EPMC2863784 | biostudies-literature
Unknown Conflicting selection pressures target the NS3 protein in hepatitis C virus genotypes 1a and 1b.
| S-EPMC3529174 | biostudies-literature
Unknown Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.
| S-EPMC4896772 | biostudies-literature